Condition: Colorectal Cancer · Sponsor: Criterium, Inc.
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
This description comes directly from the study's public registry record.
Soumaya Chappidi · 518-828-1274 · FRUQ004PM@criteriuminc.com
Julee Hartwell · 518-828-1274 · FRUQ004PM@criteriuminc.com
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Mount Sinai Cancer Research Program | Miami Beach, Florida, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| UPenn Lancaster-Ann B. Barshinger Cancer Institute | Lancaster, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Mays Cancer Center at University of Texas Health at San Antonio | San Antonio, Texas, United States | Recruiting |
| Inova Schar Cancer | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06992258